Chinese Healthcare Reforms & Industry Opportunities Examined in New In-Demand FirstWord Report Available at MarketPublishers.com27 Jul 2012 • by Natalie Aster
LONDON –China’s government announced plans to invest RMB1.13 trillion ($180 billion) in expanding and improving healthcare provision, through significant healthcare reforms in 2009.
These reforms were specifically focused on:
- expansion of medical insurance coverage;
- establishment of a national essential drug list (EDL);
- investment in improved primary healthcare facilities;
- more equal distribution of healthcare provision;
- public hospital pilot schemes;
This massive spending program is rapidly expanding healthcare access for China’s 1.3 billion citizens, and has implications for the pharmaceutical industry worldwide.
New insightful study "Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma" worked out by FirstWord has been recently published by Market Publishers Ltd.
Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
Published: June, 2012
Price: US$ 995,00
The report provides an unbiased, all-covering and analytical view at the Chinese healthcare system, developments and more precisely, reforms. It reveals the ways that recent reforms are changing healthcare for rural and urban citizens.
The report explores each key aspect of healthcare reform in turn, clearly explaining what it is, why it was needed, and what progress has been made so far, and then summarising its specific implications for the Pharma industry. As well as covering recent reforms, the report also examines key reform priorities through to 2015.
Additionally, the report provides important insights and tips for building effective relationships with Chinese stakeholders.
The report features the following data & information:
- in-depth interviews with local industry experts, including a senior policy maker at the MOHRSS and an adviser to the Ministry of Health;
- thorough review of the status of key features of the reforms announced and implemented since 2009;
- analysis of the implications of reforms for foreign pharmaceutical companies wanting to succeed in the Chinese market;
- details of reform priorities through to 2015, with their implications for Pharma;
- strategic recommendations for foreign pharmaceutical companies wanting to gain market access in China based on interviews with experts who have been involved in the launch of products in China;
- analysis of the role of distributors in China and the future of the distribution system following reforms;
- insight into the tendering process in Chinese hospitals and provinces and how to take part;
- recommendations of how to structure market access teams effectively in China.
More new market research reports by the publisher can be found at FirstWord page.